EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Ginsenoside Rb1 mitigates senescence-associated hepatic steatosis in mice through enhanced lysine degradation

Lin Wu, Qi Si, Bin Zhou, Yanyun Che, Yong Liu, Yingying Zhao, Ximei Zhang, Guangyao Shi, Baoshun Hao, Shujie Yu, Xiaoxian Qian, Jianrui Zheng und 1 weitere

Journal of Ginseng Research · 2026-07 · 50 (4) · 101026

DOI: 10.1016/j.jgr.2026.101026 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Ginseng Research, 2026-07. Verfasst von Lin Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Chinese Association of Integrative Medicine, National Natural Science Foundation of China, Zhejiang Traditional Chinese Medicine Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The liver is the central organ for metabolism and detoxification, and its function gradually declines with age, often accompanied by pathological changes such as lipid metabolism disorders, inflammatory responses, and fibrosis, significantly increasing the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH). Ginsenoside Rb1 (Rb1) is a major active constituent of ginseng. However, its regulatory mechanism on hepatic lipid metabolism and MASLD/MASH-related phenotypes during natural aging remains unclear.

Objective

To explore the effects of Rb1 on liver aging phenotypes, lipid deposition, inflammation, fibrosis, and related metabolic pathways in naturally aged mice, and to further elucidate the underlying regulatory mechanisms.

Methods

Naturally aged male C57BL/6J mice (72-week-old) were used and divided into the Old group and the Rb1 treatment group (Old + Rb1). Young mice (6-week-old) served as controls. Therapeutic effects were evaluated through histopathology (H&E, Masson trichrome, Oil Red O staining), immunofluorescence (p21, FASN, FABP1, PPARα), immunohistochemistry (PCNA, F4/80), RT-qPCR analysis of lipid metabolism-related genes. Additionally, untargeted metabolomics analyses of both serum and liver tissues, as well as liver transcriptome sequencing, were performed to investigate the underlying mechanisms.

Results

Rb1 alleviated hepatocellular senescence, as evidenced by reduced p21 expression and increased PCNA-positive cells. It ameliorated age-related hepatic pathological damage, as evidenced by reduced inflammatory infiltration (F4/80) and collagen deposition (Masson staining), along with improved hepatocellular vacuolation and lipid accumulation (Oil Red O staining). Rb1 regulated hepatic lipid metabolism through three mechanisms: inhibiting lipid synthesis (Fasn, Acaca, Srebf1), modulating lipid transport (Fabp1, Slc27a2), and promoting lipid oxidation (Pparα, Fgf21). Serum and hepatic metabolomics consistently revealed that Rb1 activated the lysine degradation pathway, accompanied by an increase in the key intermediate metabolite trimethyllysine (TML). Liver transcriptome sequencing further indicated an increasing trend in the numbers of genes associated with the biological process of metabolic process and the molecular functions of transporter activity and transcription regulator activity. Additionally, enrichment of the biological process of lipid export from the cell was observed in the comparison between the Old and Old+Rb1 groups.

Conclusion

Rb1 ameliorates age-related hepatic lipid accumulation and pathological damage in naturally aged mice by promoting the lysine degradation pathway and comprehensively remodeling lipid metabolic homeostasis. These findings provide a potential target and theoretical basis for intervention in aging-related MASLD/MASH.

Schlagwörter

Stichwörter der Autor:innen

Ginsenoside Rb1Hepatic senescenceLipid regulationLysine degradationMetabolic dysfunction-associated steatotic liver disease (MASLD)Metabolomics

Autor:innen und Institutionen

  • Department of Cardiology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China.
  • Institute of Integrated Traditional Chinese and Western Medicine, Sun Yat-sen University, Guangzhou, Guangdong, China.

Förderung

  • Chinese Association of Integrative Medicine
  • National Natural Science Foundation of China
  • Zhejiang Traditional Chinese Medicine Administration
  • Natural Science Foundation of Guangdong Province
  • Scientific and Technological Planning Project of Guangzhou City

Zitieren

APA

Wu, L., Si, Q., Zhou, B., Che, Y., Liu, Y., Zhao, Y., Zhang, X., Shi, G., Hao, B., Yu, S., Qian, X., Zheng, J., & Liu, D. (2026). Ginsenoside Rb1 mitigates senescence-associated hepatic steatosis in mice through enhanced lysine degradation. Journal of Ginseng Research, 50(4), 101026. https://doi.org/10.1016/j.jgr.2026.101026

Vancouver

Wu L, Si Q, Zhou B, Che Y, Liu Y, Zhao Y, et al. Ginsenoside Rb1 mitigates senescence-associated hepatic steatosis in mice through enhanced lysine degradation. Journal of Ginseng Research. 2026;50(4):101026. doi:10.1016/j.jgr.2026.101026

BibTeX
@article{Wu2026,
  author = {Wu, Lin and Si, Qi and Zhou, Bin and Che, Yanyun and Liu, Yong and Zhao, Yingying and Zhang, Ximei and Shi, Guangyao and Hao, Baoshun and Yu, Shujie and Qian, Xiaoxian and Zheng, Jianrui and Liu, Dinghui},
  title = {Ginsenoside Rb1 mitigates senescence-associated hepatic steatosis in mice through enhanced lysine degradation},
  journal = {Journal of Ginseng Research},
  year = {2026},
  volume = {50},
  number = {4},
  pages = {101026},
  doi = {10.1016/j.jgr.2026.101026}
}
Kostenlos starten →